NASDAQ: GNPX · Life Sciences · 5 alerts · CIK 1595248
Share price
$1.90Close, Nov 16
Market cap
$2.54M
Shares outstanding
1.33MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Genprex, Inc. filings on SEC EDGAR ↗
Genprex, Inc. reported a net loss of $13.1 million for the nine months ended September 30, 2026, compared to $12.4 million in the prior year period. The company significantly strengthened its cash position to $15.3 million through $18.7 million in net proceeds from common stock issuances, supporting its ongoing clinical development of gene therapies for oncology and diabetes.
Genprex announced translational analysis results from 11 lung cancer patients treated with its lead gene therapy candidate, Reqorsa (quaratusugene ozeplasmid). The data, presented at the GSA 2026 Annual Scientific Meeting, showed that Reqorsa administration triggers a transcriptional shift toward cellular maintenance, mitochondrial adaptation, and autophagy by 24 hours post-treatment. These findings suggest the TUSC2 gene delivered by Reqorsa enhances cellular resilience to aging-associated stress and deepens the company's understanding of the drug's biological impact.
Genprex announced new research identifying TROP2 expression as a potential predictive biomarker for response to its lead gene therapy candidate, Reqorsa, in non-small cell lung cancer (NSCLC). Data from preclinical models and patient biopsies showed that low TROP2 expression is associated with resistance to treatment, which could help the company select more applicable patients for future clinical trials.
Genprex announced that research from its sponsored collaboration with Meharry Medical College will be presented at the Gerontological Society of America 2026 Annual Scientific Meeting. The research explores the role of the TUSC2 gene, used in the company's lead candidate REQORSA, in cellular resilience and molecular processes associated with aging. This data may inform potential future therapeutic applications for REQORSA beyond its current focus on oncology and diabetes.
Genprex highlighted peer-reviewed preclinical research published in Mechanisms of Ageing and Development regarding the TUSC2 gene, which is the therapeutic component of its REQORSA oncology program. The study found that TUSC2 deficiency in mice leads to mitochondrial dysfunction and protein homeostasis collapse in the brain, with human datasets showing TUSC2 expression also declines with age and Alzheimer's disease. While exploratory, the findings suggest TUSC2 plays a foundational role in brain health beyond its established role in cancer treatment.